Peters Brandilyn A, Hall Megan N, Liu Xinhua, Slavkovich Vesna, Ilievski Vesna, Alam Shafiul, Siddique Abu B, Islam Tariqul, Graziano Joseph H, Gamble Mary V
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Environ Res. 2015 Nov;143(Pt A):123-30. doi: 10.1016/j.envres.2015.10.001. Epub 2015 Oct 19.
Arsenic (As) methylation capacity in epidemiologic studies is typically indicated by the proportions of inorganic As (%InAs), monomethylarsonic acid (%MMA), and dimethylarsinic acid (%DMA) in urine as a fraction of total urinary As. The relationship between renal function and indicators of As methylation capacity has not been thoroughly investigated.
Our two aims were to examine (1) associations between estimated glomerular filtration rate (eGFR) and %As metabolites in blood and urine, and (2) whether renal function modifies the relationship of blood %As metabolites with respective urinary %As metabolites.
In a cross-sectional study of 375 As-exposed Bangladeshi adults, we measured blood and urinary As metabolites, and calculated eGFR from plasma cystatin C.
In covariate-adjusted linear models, a 1 ml/min/1.73 m(2) increase in eGFR was associated with a 0.39% increase in urinary %InAs (p<0.0001) and a mean decrease in urinary %DMA of 0.07 (p=0.0005). In the 292 participants with measurable blood As metabolites, the associations of eGFR with increased blood %InAs and decreased blood %DMA did not reach statistical significance. eGFR was not associated with urinary or blood %MMA in covariate-adjusted models. For a given increase in blood %InAs, the increase in urinary %InAs was smaller in those with reduced eGFR, compared to those with normal eGFR (p=0.06); this effect modification was not observed for %MMA or %DMA.
Urinary excretion of InAs may be impaired in individuals with reduced renal function. Alternatively, increased As methylation capacity (as indicated by decreased urinary %InAs) may be detrimental to renal function.
在流行病学研究中,砷(As)的甲基化能力通常通过尿液中无机砷(%InAs)、一甲基胂酸(%MMA)和二甲基胂酸(%DMA)占总尿砷的比例来表示。肾功能与砷甲基化能力指标之间的关系尚未得到充分研究。
我们的两个目标是研究(1)估计肾小球滤过率(eGFR)与血液和尿液中砷代谢产物百分比之间的关联,以及(2)肾功能是否会改变血液中砷代谢产物百分比与相应尿液中砷代谢产物百分比之间的关系。
在一项对375名接触砷的孟加拉国成年人的横断面研究中,我们测量了血液和尿液中的砷代谢产物,并根据血浆胱抑素C计算eGFR。
在协变量调整的线性模型中,eGFR每增加1 ml/min/1.73 m²,尿中%InAs增加0.39%(p<0.0001),尿中%DMA平均降低0.07(p=0.0005)。在292名血液中砷代谢产物可测量的参与者中,eGFR与血液中%InAs增加和血液中%DMA降低之间的关联未达到统计学意义。在协变量调整模型中,eGFR与尿或血液中的%MMA无关。对于血液中%InAs的给定增加,与eGFR正常的人相比,eGFR降低的人尿中%InAs的增加较小(p=0.06);对于%MMA或%DMA未观察到这种效应修饰。
肾功能降低的个体中,InAs的尿排泄可能受损。或者,砷甲基化能力增加(如尿中%InAs降低所示)可能对肾功能有害。